GILD

Gilead Sciences
D

GILD

Arincen87/100B
166.870
USD
-0.73
(-0.44%)
Pre Open·168.040USD+1.170(+0.70%)
Last updated: · Delayed 15 min
Q4 FY2026 · Earnings report
EPS estimate 1.39Revenue estimate 8.28B
OverviewFinancialsForecastEarningsDividendsCompany

Gilead Sciences revenue 1990–2026

Gilead Sciences's revenue in Q3 FY2026, the three months to 30 September 2026, was 8.30B USD, up 6.8% on the same quarter a year before. Gilead Sciences's revenue over the last twelve months was 30.99B USD, up 6.5% on the twelve months before. In fiscal year 2025 it was 29.44B USD, up 2.4% on the year before.

Last updated 9 Nov 2026 · Next report 9 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 202630.99B+6.54%24.77B-3.86B
FY202531 Dec 202529.44B+2.39%23.21B8.51B
FY202431 Dec 202428.75B+6.04%22.50B480.00M
FY202331 Dec 202327.12B-0.60%20.62B5.67B
FY202231 Dec 202227.28B-0.09%21.62B4.59B
FY202131 Dec 202127.31B+10.60%20.70B6.23B
FY202031 Dec 202024.69B+9.98%20.12B123.00M
FY201931 Dec 201922.45B+1.46%17.77B5.39B
FY201831 Dec 201822.13B-15.24%17.27B5.46B
FY201731 Dec 201726.11B-14.09%21.74B4.63B
FY201631 Dec 201630.39B-6.89%26.13B13.50B
FY201531 Dec 201532.64B+31.13%28.63B18.11B
FY201431 Dec 201424.89B+122.19%21.10B12.10B
FY201331 Dec 201311.20B+15.46%8.34B3.08B
FY201231 Dec 20129.70B+15.70%7.23B2.59B
FY201131 Dec 20118.39B+5.48%6.26B2.80B
FY201031 Dec 20107.95B+13.38%6.08B2.90B
FY200931 Dec 20097.01B+31.40%5.42B2.64B
FY200831 Dec 20085.34B+26.14%4.21B1.98B
FY200731 Dec 20074.23B+39.78%3.46B1.62B
FY200631 Dec 20063.03B+49.19%2.59B-1.19B
FY200531 Dec 20052.03B+53.13%1.77B813.91M
FY200431 Dec 20041.32B+52.63%1.16B449.37M
FY200331 Dec 2003867.86M+85.92%755.17M-72.00M
FY200231 Dec 2002466.79M+99.68%397.07M72.10M
FY200131 Dec 2001233.77M+19.54%190.01M52.27M
FY200031 Dec 2000195.56M+15.71%162.04M-56.78M
FY199931 Dec 1999169.00M+11.85%152.10M-66.50M
FY199831 Dec 1998151.10M+14.21%140.90M-44.80M
FY199731 Dec 1997132.30M+296.11%125.90M-72.90M
FY199631 Dec 199633.40M+1,137.04%37.00M-21.70M
FY199531 Dec 19952.70M-44.90%5.90M-27.40M
FY199431 Dec 19944.90M+16.67%8.80M-31.30M
FY199231 Dec 19924.20M+50.00%5.90M-14.10M
FY199131 Dec 19912.80M+115.38%3.80M-4.50M
FY199031 Dec 19901.30M—2.10M-4.00M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Gilead Sciences revenue growth by segment

Q3 FY2026 against Q3 FY2025

Other HIV6.25B
+18.4%
Trodelvy506.00M
+41.7%
Cell Therapy Products, Total Cell Therapy Product Sales415.00M
-19.4%
Other Products, Total Other product sales167.00M
-9.2%
Veklury86.00M
-69.0%

Gilead Sciences revenue by segment over time

Biktarvy Descovy Genvoya Yescarta Trodelvy Sofosbuvir/Velpatasvir Odefsey Vemlidy Veklury Other Liver Disease Royalty, contract and other revenues AmBisome Other HIV Symtuza - Revenue share Tecartus Other Ranexa Viread Atripla Epclusa Harvoni Sovaldi Truvada Zydelig Letairis Stribild Other Products Complera Eviplera Antiviral Products Other antiviral products Vosevi Other Products, Total Other product sales Cell Therapy Products, Total Cell Therapy Product Sales Hepatitis B Virus / Hepatitis Delta Virus Product
Fiscal yearBiktarvyDescovyGenvoyaYescartaTrodelvySofosbuvir/VelpatasvirOdefseyVemlidyVekluryOther Liver DiseaseRoyalty, contract and other revenuesAmBisomeOther HIVSymtuza - Revenue shareTecartusOtherRanexaVireadAtriplaEpclusaHarvoniSovaldiTruvadaZydeligLetairisStribildOther ProductsComplera EvipleraAntiviral ProductsOther antiviral productsVoseviOther Products, Total Other product salesCell Therapy Products, Total Cell Therapy Product SalesHepatitis B Virus / Hepatitis Delta Virus Product
FY202514.33B 2.76B 1.50B 1.50B 1.40B +6.2%1.27B 1.17B 1.07B 911.00M -49.4%874.00M 527.00M 509.00M 500.00M -97.5%495.00M 344.00M 290.00M — — — — — — — — — — — — — — — — — —
FY2024— — — — 1.32B +23.7%— — — 1.80B -17.6%— — — 19.61B +7.6%— — — — — — — — — — — — — — — — — — 889.00M +3.5%2.38B +6.1%—
FY2023— — — — 1.06B +56.3%— — — 2.18B -44.1%— — — 18.23B +5.7%— — — — — — — — — — — — — — — — — — 859.00M -9.2%2.24B +27.4%1.02B +2.9%
FY2022— — — — 680.00M +78.9%— — — 3.91B -29.8%— — — 17.25B +5.4%— — — — — — — — — — — — — — — — — — 946.00M -7.9%1.76B +67.9%988.00M +2.0%
FY2021— — — — 380.00M — — — 5.57B — — — 16.37B -3.7%— — — — — — — — — — — — — — — — — — 1.03B -45.5%1.05B +72.5%969.00M
FY2020— — — — — — — — — — — — 17.00B +36,061.7%— — — — — — — — — — — — — — — — — — 1.89B 607.00M —
FY2019— — — — — — — — — — — — 47.00M -23.0%— — — — — — — — — — — — — — — — — — — — —
FY2018— — — — — — — — — — — — 61.00M — — — — — — — — — — — — — — — — — — — — —
FY2017— 1.22B +308.7%3.67B +147.6%— — — 1.11B +236.2%— — — — 366.00M +2.8%— — — — 717.00M +5.9%1.05B -11.8%1.81B -30.7%3.51B +100.3%4.37B -51.9%964.00M -75.9%3.13B -12.1%149.00M -11.3%887.00M +8.3%1.05B -45.0%207.00M +10.1%966.00M -33.7%23.34B -15.9%196.00M +172.2%293.00M — — —
FY2016— 298.00M 1.48B +3,197.8%— — — 329.00M — — — — 356.00M +1.7%— — — — 677.00M +15.1%1.19B +7.0%2.61B -16.9%1.75B 9.08B -34.5%4.00B -24.2%3.57B +3.1%168.00M +27.3%819.00M +17.0%1.91B +4.9%188.00M +8.0%1.46B +2.1%27.75B -8.2%72.00M +4.3%— — — —

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Gilead Sciences's revenue

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.